

(I) $Z_1 \sim Z_2 - X_1 - X_2 - X_3 - X_4 - X_5 - X_6 - X_7 - X_8 - X_9 - X_{10} - Z_3 \sim Z_4$

or a pharmaceutically-acceptable salt thereof, wherein:

Z_1 is $R-C(O)-NR-$ or $RRN-$;

Z_2 is an optional 1 to 5 residue peptide or peptide analog;

X_1 is any amino acid residue;

X_2 is any amino acid residue;

X_3 is a hydrophobic residue or a hydroxyl-substituted aliphatic residue;

X_4 is any amino acid residue;

X_5 is a hydrophobic residue or Gly;

X_6 is a hydrophobic or a hydrophilic residue;

X_7 is Gly, an amide-substituted polar residue or a hydrophobic residue;

X_8 is any amino acid residue;

X_9 is an aliphatic residue;

X_{10} is any amino acid residue;

Z_3 is an optional 1 to 5 residue peptide or peptide analog;

Z_4 is $-C(O)OR$ or $-C(O)NRR$;

each R is independently hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl or (C_6-C_{14}) aryl;

each "-" between residues X_1 through X_{10} , Z_2 and X_1 and X_{10} and Z_3 independently represents an amide linkage, a substituted amide linkage or an isostere of an amide linkage; and

each "~" represents a bond.

Substitute the following for claim 4:


4. (once amended) The compound of claim 1 wherein the mimic comprises a mimic of a chaperone G_1 beta-strand with at least two alternating hydrophobic amino acid residues which exhibits antibacterial activity against a Gram-negative bacterium.

Substitute the following for claim 8:

8. (once amended) The compound of claim 1 wherein the mimic comprises a mimic of an amino terminal motif of a pilus subunit selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28 and SEQ ID NO: 29.

Substitute the following from claim 12:

12. (once amended) The compound of claim 1 which is a 10-20 residue peptide or peptide analog according to formula (I):



or a pharmaceutically-acceptable salt thereof, wherein:

Z_1 is R-C(O)-NR- or RRN-;

Z_2 is an optional 1 to 5 residue peptide or peptide analog;

X_1 is any amino acid residue;

X_2 is any amino acid residue;

X_3 is a hydrophobic residue or a hydroxyl-substituted aliphatic residue;

X_4 is any amino acid residue;

X_5 is a hydrophobic residue or Gly;

X_6 is a hydrophobic or a hydrophilic residue;

X_7 is Gly, an amide-substituted polar residue or a hydrophobic residue;

X_8 is any amino acid residue;

X_9 is an aliphatic residue;

X_{10} is any amino acid residue;

Z_3 is an optional 1 to 5 residue peptide or peptide analog;

Z_4 is -C(O)OR or -C(O)NRR;

20

each R₁ is independently hydrogen, C_1C_6 alkyl, C_2C_6 alkenyl, C_2C_6 alkynyl or C_6C_{14} aryl;

each "-" between residues X₁ through X₁₀, Z₂ and X₁ and X₁₀ and Z₃ independently represents an amide linkage, a substituted amide linkage or an isostere of an amide linkage; and

each "~" represents a bond.

Substitute the following for claim 14:

14. (once amended) The compound of claim 13 which is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28 and SEQ ID NO: 29.

Please cancel claims ~~3, 18~~ and 22-135.

In the Drawings:

Please replace the drawings originally submitted with the formal drawings enclosed.

*